157 related articles for article (PubMed ID: 27534815)
1. Biochemical Characterization of APOBEC3H Variants: Implications for Their HIV-1 Restriction Activity and mC Modification.
Gu J; Chen Q; Xiao X; Ito F; Wolfe A; Chen XS
J Mol Biol; 2016 Nov; 428(23):4626-4638. PubMed ID: 27534815
[TBL] [Abstract][Full Text] [Related]
2. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
[TBL] [Abstract][Full Text] [Related]
3. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
Ooms M; Majdak S; Seibert CW; Harari A; Simon V
J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
[TBL] [Abstract][Full Text] [Related]
4. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.
Wang X; Abudu A; Son S; Dang Y; Venta PJ; Zheng YH
J Virol; 2011 Apr; 85(7):3142-52. PubMed ID: 21270145
[TBL] [Abstract][Full Text] [Related]
5. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.
Mitra M; Singer D; Mano Y; Hritz J; Nam G; Gorelick RJ; Byeon IJ; Gronenborn AM; Iwatani Y; Levin JG
Retrovirology; 2015 Jan; 12():3. PubMed ID: 25614027
[TBL] [Abstract][Full Text] [Related]
6. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
Zhen A; Du J; Zhou X; Xiong Y; Yu XF
PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
Ooms M; Krikoni A; Kress AK; Simon V; Münk C
J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H.
Ito F; Yang H; Xiao X; Li SX; Wolfe A; Zirkle B; Arutiunian V; Chen XS
Sci Rep; 2018 Feb; 8(1):3763. PubMed ID: 29491387
[TBL] [Abstract][Full Text] [Related]
9. Family-Wide Comparative Analysis of Cytidine and Methylcytidine Deamination by Eleven Human APOBEC Proteins.
Ito F; Fu Y; Kao SA; Yang H; Chen XS
J Mol Biol; 2017 Jun; 429(12):1787-1799. PubMed ID: 28479091
[TBL] [Abstract][Full Text] [Related]
10. Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability.
Feng Y; Love RP; Ara A; Baig TT; Adolph MB; Chelico L
J Biol Chem; 2015 Nov; 290(45):27188-27203. PubMed ID: 26396192
[TBL] [Abstract][Full Text] [Related]
11. Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.
Ebrahimi D; Richards CM; Carpenter MA; Wang J; Ikeda T; Becker JT; Cheng AZ; McCann JL; Shaban NM; Salamango DJ; Starrett GJ; Lingappa JR; Yong J; Brown WL; Harris RS
Nat Commun; 2018 Oct; 9(1):4137. PubMed ID: 30297863
[TBL] [Abstract][Full Text] [Related]
12. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
Ooms M; Letko M; Binka M; Simon V
PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
[TBL] [Abstract][Full Text] [Related]
13. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
Dang Y; Siew LM; Wang X; Han Y; Lampen R; Zheng YH
J Biol Chem; 2008 Apr; 283(17):11606-14. PubMed ID: 18299330
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vif adaptation to human APOBEC3H haplotypes.
Ooms M; Brayton B; Letko M; Maio SM; Pilcher CD; Hecht FM; Barbour JD; Simon V
Cell Host Microbe; 2013 Oct; 14(4):411-21. PubMed ID: 24139399
[TBL] [Abstract][Full Text] [Related]
15. The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism.
Shaban NM; Shi K; Lauer KV; Carpenter MA; Richards CM; Salamango D; Wang J; Lopresti MW; Banerjee S; Levin-Klein R; Brown WL; Aihara H; Harris RS
Mol Cell; 2018 Jan; 69(1):75-86.e9. PubMed ID: 29290613
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.
Li MM; Emerman M
J Virol; 2011 Aug; 85(16):8197-207. PubMed ID: 21653666
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.
Harari A; Ooms M; Mulder LC; Simon V
J Virol; 2009 Jan; 83(1):295-303. PubMed ID: 18945781
[TBL] [Abstract][Full Text] [Related]
19. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.
Starrett GJ; Luengas EM; McCann JL; Ebrahimi D; Temiz NA; Love RP; Feng Y; Adolph MB; Chelico L; Law EK; Carpenter MA; Harris RS
Nat Commun; 2016 Sep; 7():12918. PubMed ID: 27650891
[TBL] [Abstract][Full Text] [Related]
20. Different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus.
Kanagaraj A; Sakamoto N; Que L; Li Y; Mohiuddin M; Koura M; Wakae K; Kurachi M; Muramatsu M; Kitamura K
Biochem Biophys Res Commun; 2019 Oct; 518(1):26-31. PubMed ID: 31400856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
